A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C
NCT ID: NCT01908335
Last Updated: 2014-10-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
212 participants
INTERVENTIONAL
2012-10-31
2014-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C
NCT01903278
Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection
NCT02716779
CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
NCT00277238
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
NCT01725529
Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)
NCT01606800
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A (PEG-IFN-SA /RBV low dose)
PEG-IFN-SA 0.75μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW\<75kg，1000mg/d；BW≥75kg，1200mg/d）
PEG-IFN-SA /RBV low dose
24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
B (PEG-IFN-SA /RBV middle dose)
PEG-IFN-SA 1.5μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW\<75kg，1000mg/d；BW≥75kg，1200mg/d）
PEG-IFN-SA /RBV middle dose
24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
C (PEG-IFN-SA /RBV high dose)
PEG-IFN-SA 2.0μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW\<75kg，1000mg/d；BW≥75kg，1200mg/d）
PEG-IFN-SA /RBV high dose
24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
D (Pegasys /RBV)
Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW\<75kg，1000mg/d；BW≥75kg，1200mg/d）
Pegasys /RBV
24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PEG-IFN-SA /RBV low dose
24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
PEG-IFN-SA /RBV middle dose
24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
PEG-IFN-SA /RBV high dose
24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
Pegasys /RBV
24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body Mass Index (BMI) 18-30
* Chronic hepatitis C , diagnosed according to Chinese guideline of Hepatitis C (year 2004)
* Detectable serum HCV-RNA by quantitative polymerase chain reaction assay and positive anti-HCV antibody
* Female subjects of childbearing age with no history of menopause and negative pregnancy test, both female and male( including their partners ) subjects were required to conduct adequate contraception since screening until the 6 months after treatment
* Volunteered to participate in this study, understood and signed an informed consent
Exclusion Criteria
* Co-infection with HAV, HBV, HEV, EBV, CMV and HIV
* Evidences of hepatic decompensation, including but not limited to serum total bilirubin\> 2 times the upper limit of normal (ULN); serum albumin \<35g/L; prothrombin activity (PTA) \<60%; ascites, upper gastrointestinal bleeding and hepatic encephalopathy; Child-Pugh score B/C grade
* Hepatotoxic drugs was used for a long time within past 6 months
* Diagnosed with primary hepatocellular carcinoma or supported by evidences including but not limited to AFP\> l00ng/ml, suspicious liver nodules by imaging examinations
* Liver diseases from causes other than HCV infection, including alcoholic liver disease, non-alcoholic steatohepatitis, drug-induced hepatitis, autoimmune hepatitis (antinuclear antibody titer higher than 1:100), hepatolenticular degeneration (Wilson's disease) and hemochromatosis, etc.
* White blood cell count \<3×109/L; Neutrophil count\<1.5×109/L; platelet count\<90×109/L; hemoglobin below the lower limit of normal
* Serum creatinine not within the normal range
* Serum creatine kinase\> 3 ULN
* Positive thyroid antibodies (A-TPO, A-TG)
* Therapy with potent immunomodulatory agents such as adrenocorticotropic hormone, thymosin α1 etc. within past 6 months or an anticipated usage during the period of study
* Allergies or severe allergies, especially allergic to study drugs or any ingredients of the study drugs
* Severe autoimmune diseases; psychiatric and nervous system disorders, including history of Psychiatric illness or with family history (especially depression, depressive tendencies, epilepsy and hysteria, etc.); Serious blood disorders (all kinds of anemia, hemophilia, etc.); Severe kidney disease (chronic kidney disease, renal insufficiency, etc.); poorly controlled digestive diseases; endocrine disorders such as thyroid disease and diabetes; severe respiratory disease (pneumonia, chronic obstructive pulmonary disease, interstitial lung disease, etc.); cardiovascular diseases (hypertension, uncontrolled coronary atherosclerotic heart disease, heart failure, etc.); retinal disease; malignancies; or unsuitable for study considered by clinician
* Function organs transplant
* Evidence of alcohol or drug abuse (average alcohol consumption male\> 40g / day, female\> 20g / day)
* Pregnant or lactating women
* Usage of prohibition drugs in this study
* Participated in other clinical trials 3 months prior to the screening
* Unwilling to sign the informed consent and adhere to treatment requirements
* Other conditions not suitable for study judged by investigators
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Kawin Technology Share-Holding Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cheng jun
vice president
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cheng jun, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Beijing Ditan Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
First Affiliated Hospital of Lanzhou University
Lanzhou, Gansu, China
Guangdong General Hospital
Guangzhou, Guangdong, China
Guangzhou Eighth People's Hospital
Guangzhou, Guangdong, China
Nanfang Hospital Southern Medical Unbiversity
Guangzhou, Guangdong, China
The third people's hospital of Shenzhen
Shenzhen, Guangdong, China
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
Third Affiliated Hospital, Hebei Medical University
Shijiazhuang, Hebei, China
The First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China
First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Henan Provincial People's Hospital
Zhengzhou, Henan, China
Tongji Hospital, Tongji Medical College Huazhong University of Science ＆ Technology
Wuhan, Hubei, China
Union hospital, Tongji Medical College Huazhong University of Science ＆ Technology
Wuhan, Hubei, China
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Xiangya Hospital Central-South University
Changsha, Hunan, China
Jiangsu province hospital
Nanjing, Jiangsu, China
The Second Hospital of Nanjing
Nanjing, Jiangsu, China
The first affiliated hospital of suzhou university
Suzhou, Jiangsu, China
First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
The First Affiliated Hospital of Jilin University
Changchun, Jilin, China
Yanbian University Hospital (Yanbian Hospital)
Yanji, Jilin, China
The Sixth People's Hospital of Shenyang
Shenyang, Liaoning, China
First Affiliated Hospital Of Medical College of Xian Jiaotong University
Xi'an, Shaanxi, China
Second Affiliated Hospital Of Medical College of Xian Jiaotong University
Xi'an, Shaanxi, China
Tangdu Hospital , , Fourth Military Medical University
Xi'an, Shaanxi, China
Jinan Infectious Disease Hospital
Jinan, Shandong, China
Qilu Hospital of Shandong university
Jinan, Shandong, China
Shandong Provincial Hospital
Jinan, Shandong, China
Qingdao Municipal Hospital
Qingdao, Shandong, China
The First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Sichuan Academy of Medical Science ＆Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
The First Teaching Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
Xixi Hospital of Hangzhou
Hangzhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
302 Military Hospital of China
Beijing, , China
Beijing Ditan Hospital, Capital Medical University
Beijing, , China
Beijing Youan Hospital, Capital Medical University
Beijing, , China
Beijing Youyi Hospital, capital Medical University
Beijing, , China
General Hospital of Beijing Military Region
Beijing, , China
Peking Union Medical College Hospital
Beijing, , China
Peking University First Hospital
Beijing, , China
Peking University People's Hospital
Beijing, , China
Chongqing Southwest Hospital
Chongqing, , China
Daping Hospital, Research Institute of Surgery Third Military Medical University
Chongqing, , China
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, , China
Ruijing Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, , China
Shanghai Public Health Clinical Center
Shanghai, , China
Tianjin Infectious Disease Hospital
Tianjin, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KAWIN-002-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.